MetroNome is a web-based visual data exploration platform which integrates de-identified 14 genomic, transcriptomic, and phenotypic data sets. Users can define and compare cohorts 15 constructed from multimodal data and share the data and analyses with outside tools. MetroNome's 16 interactive visualization and analysis tools allow researchers to quickly form and explore novel 17 hypotheses. The deidentified data is linked back to the source biosample inventories in multiple 18 biobanks, enabling researchers to further investigate new ideas using the most relevant samples. 19
Introduction 20
Biomedical research is producing a wealth of genomic data, some of it public [1] ; though much is 21 restricted to various consortia or project team members. The restrictions are often necessary to 22 comply with consents and regulatory policies. Analyses of complex multimodal patient-derived 23 data-such as genome sequencing, clinical and pathological measures, environmental factors, and 24 imaging-enables questions to be explored that would otherwise not be possible. For example, how 25 can the same chromatin remodeling genes be associated with autism, schizophrenia, bipolar 26 disorder, congenital heart defects, and digestive tract issues? To achieve adequate statistical power 27 for genomic research discoveries, different types of data -from different studies and diseases -28 must be integrated while assuring regulatory compliance with patient confidentiality and data use 29 policies [2, 3, 4, 6]. The associated tools should be openly available and usable by a wide audience 30
with different levels of expertise in genomics and biostatistics, while still ensuring responsible use of 31 the data. Existing applications make it possible to integrate GWAS results with other data to 32 prioritize variants by phenotype [7] or browse available individual-level genotype and sequence data associated with phenotypic features [8] . However, these tools generally lack the capability to then 34 generate lists of samples and subjects matching genomic and phenotypic criteria of interest, enabling 35 access to the underlying de-identified data and samples across multiple biorepositories. 36 MetroNome comprises a web-based suite of interactive data visualization tools, enabling users to 37 combine their own data with other relevant public datasets and explore the results via linked graphs 38 and diagrams. The system leverages human visuospatial cognitive abilities to reveal patterns and find 39 on the same screen and the ability to filter on any one frame and propagate that filter to all other 57 frames on the dashboard. This dynamic queries technique initially arose as an alternative to SQL for 58 querying databases [5] . MetroNome unites these two directions: scientific and statistical 59 visualizations, combined with dynamic filtering and filter propagation. 60
Exploration of synthetic cohorts via multi-modal interactive data visualization 61
MetroNome presents genomic and transcriptomic data in the context of phenotypic attributes, 62 relying on customized linked visualizations to enable exploration. 63
Creating synthetic cohorts 64 We allow the user to combine and display data from multiple sources, based on phenotypic or 65 genotypic traits and user access rights to those datasets. We provide access to publicly available 66 reference datasets, such as 1000 genomes [12] and TCGA tumor data [13] for use as comparators. To 67 perform an analysis, the user starts by creating a query that selects data from one or multiple sources. MetroNome's query page presents a series of dynamically linked drop-down menus that can 69 be combined into rules for selecting subjects. Rules for subject and sample criteria can include filters 70 for any information available in the datasets that the user has selected for inclusion. Genomic rules 71
can include the presence of variants in a list of genes or in a genomic region. Variants can be filtered 72 by their predicted protein-coding impact as calculated by SnpEff [9], or their association with 73 disease as recorded in ClinVar [10]. The search produces lists of subjects, samples, and variants that 74 match the selected rules. 75
Multi-modal visualization and refinement of cohorts Comparison of cohorts 96 We provide the ability to view two cohorts side-by-side, to allow comparisons of traits that might 97
influence results and warrant further study. Visually comparing datasets is one way to determine 98 whether given cohorts are of interest, and whether specific dynamic filters better isolate features of 99 interest. Cohort-normalized values, such as gene expression z-scores, are recalculated on the fly, 100
based on the user's search parameters, to accurately represent critical differences between groups, 101 e.g., cases and controls. between the two groups in the primary motor cortex and, for the cohort with repeat expansions 108 (left), the motor cortex vs. occipital cortex, an uninvolved region. In the relationship diagrams, this 109 cohort is also marked by shorter duration of the disease. 110 111 Figure 2 shows a query for samples with variants in the gene PFN1, requested by a researcher who 112 had seen white matter abnormalities in mouse spinal cords. The neuro axis diagram clearly shows 113 higher PFN1 expression in the spinal cord, and particularly in the thoracic spinal cord, which is 114
interesting because the thoracic cord has a higher proportion of white matter compared to cervical 115 and lumbar. In addition, the RNA heatmap indicates that there are a couple of specific samples with 116 Infrastructure to support cross-study dynamic visualization 127 In addition to the visualization tools themselves, a great deal of data infrastructure is needed to 128 realize the outlined goals. These infrastructure tools center on integrating data with available 129 standards and with other data across multiple studies. We outline here three areas we have found 130 necessary to address: 131
• Data harmonization: We harmonize data where possible, which is currently a manual process. 132 Fields with different names in different datasets must be changed to the same standard names in 133 each. The values of those fields must be converted to the same vocabulary, the same numeric 134 ranges, and the same units. Values that are in reference to a specified or assumed range, such as 135 values from some laboratory tests that have varying ranges by instrument used, must be recorded 136 along with the reference range. Missing values must be handled, whenever possible, without 137 discarding the entire record. 138
• Use of metadata and provenance: the data needed for analyzing results for a single study are 139 often insufficient for integrating that data with information from other sources. Where the 140 metadata and provenance data exist, we use such information to more accurately present 141 combined data. We flag uncertainties to minimize misleading results. 142
• Reference data: to enable as much data integration as possible, we maintain significant types 143 of reference data, including target sets for standard exome kits. ClinVar [clinvar.org] 144 annotations are used to filter for pathogenic variants. Ensembl transcript-level and protein 145 domain annotations provide information on protein-coding impact and high-impact variants, 146 when disease significance is still unknown. 1,000 Genomes and TCGA somatic data are 147 maintained, primarily as sources of additional data for sparse datasets. These reference data are 148 used for comparisons, for interpretation of metadata, and for annotation of the synthesized 149 cohorts generated in MetroNome. Note that full data integration to enable further analysis is a 150 much more extensive problem that we have yet to address. Our work here is focused on enabling 151 integrated and comparative visualizations. 152
Privacy and security 153 Privacy and security are major concerns when we are supporting limited-access datasets. 154
Authorization to access a particular dataset is determined by the owner of that dataset. The NYGC 155
Data Privacy Committee must review the owner's approval before access is granted within 156
MetroNome. While this is a somewhat burdensome process, we feel it necessary to ensure that we 157
can host private data without risk of unintentional disclosure. If a user is approved for access, they 158
can grant members of their lab further access without review. This last case happens most often 159 when a user is part of a consortium, and the official owner of the data is their institution. The one 160 exception to that rule is that we allow users to upload any dataset to which they already have access, 161 limited to personal access only, and combine it with other MetroNome datasets they can access. 162
The MetroNome backend adds a clause to every database query to restrict the query to the set of 163 samples to which the user has access. Currently, users can access public data without logging in. If 164 they do so, the backend defaults to the "public" user, with associated access rights, and limits all 165 queries to public data only. Thus, no query or request can bypass the front end and avoid the 166 privacy checks. 167
The MetroNome front-end runs in an isolated subnet, accessible from outside the firewall. The 168 database and middle tier run behind the firewall, and all data thus resides internally. There is a 169 single connection through that firewall, restricted to a single machine address. clinically effective therapies, a crucial aim was to address the substantial unmet need for high quality 193 patient-derived biosamples -such as brain, spinal cord, and muscle tissue samples from patients who 194 died from ALS and controls, and biofluids and stem-cell lines collected during disease progression. 195 We perform centralized Whole Genome Sequencing (WGS), and RNA-Seq for multiple central • find variants or RNA expression changes in specific targets; 212
• provide "clean controls" that do not possess mutations or unknown variants; 213
• compare spatial expression patterns with published imaging biomarker data meant to 214 quantify relevant pathways; 215
• examine whether gene expression patterns are consistent with activation of pathways 216 modulated by potential new drug candidates; 217
• identify whether specific patient subgroups display gene signatures that might inform 218 patient selection for clinical trials (Figure 3) ; 219
• segregate patients based on spatial gene expression patterns and correlate with fast/slow 220 progressors, site of onset, or specific neuropathological metadata; 221
• design further collaborative analysis of the genetic raw data and samples, such as whether 222 subject groups with distinct genetic patterns might correlate with biomarker profiles in 223 fluids or peripheral tissues. 224 225
The MetroNome visual data exploration platform has proven critical to the continued success, 226 expansion, and evolution of the Target ALS Postmortem Core and associated efforts. It has 227 supported over 100 different academic and industry labs, facilitating more than 135 different ALS 228 research projects in 16 countries across 4 continents. This often includes multiple different projects 229 in each lab. MetroNome has become part of a scientific ecosystem that includes clinics, research 230 labs, and industry. 231
General use 232
MetroNome is unbiased towards specific disease areas and can accommodate genomic and 233 phenotypic data from any study. Figure 3 shows an example from an esophageal cancer study, 234
indicating presence of single-nucleotide variants, copy number variations, and structural variations 235 for a matrix of genes and samples. 236 237 Future work 238 New releases will include some additional critical features: 239
• Download images from our visualizations, along with the metadata about the cohort 240 being used and the filters applied. 241
• Automate the process for users to upload their own datasets, visible only to them. 242
• Improve reproducibility: users will be able to save queries, to rerun them in a later 243 session, or share them with other users. The ability to save results, and access them later, 244
should underlying data change in the interim, is planned. Finally, tracking the steps a 245 user executes in a session, displaying that history and allowing a user to return to a 246 previous state is a feature we believe to be very useful in this context. 247
• Add support and visualizations for new data types, such as repeat expansions and splice 248 junctions. We expect the types of data to expand continually. 249
• Automate harmonization using HPO terms [15] . 250
• Pedigree relationships, including flagging filtered de novo or recessive homozygous 251 variants in the probands. Our structure allows subjects to be considered probands in one 252 study and relatives in others. 253 samples. The grey callout shows details for one gene in one sample. Single-nucleotide variants are identified as high or moderate impact. Copy number changes and structural variants are identified by special glyphs and colors. Sorted by default to show genes and samples with the most impactful variants, this matrix can be used to select samples and genes (yellow area), e.g., to create a synthetic cohort prioritizing highly mutated samples.
• To aid evaluation of results, we want to integrate statistical analysis tools. We may link 254 out to R, to BioConductor tools [www.bioconductor.org], or to tools such as DeepSea 255 [16] . 256
• APIs to allow MetroNome to exchange both data and compute with other repositories. 257
These APIs are essential to users who wish to use the MetroNome resources with their 258 automated analyses, rather than through our visualization interface. 259
• Develop user interfaces for longitudinal data 260 Summary 261 Synthesizing cohorts by integrating data from multiple studies presents numerous challenges. 262
Providing this functionality as part of an interactive phenotype-genotype visualization platform 263 enables data integration as a fundamental part of the platform. Not only does this approach enhance 264 integrated multi-modal analysis, it provides a framework that reduces the work each researcher must 265 perform to obtain a clean cohort that meets their research needs. Using this visual data integration 266 platform to generate and explore hypotheses is a further important contribution, with the potential 267 to accelerate the work of scientists anywhere by eliminating the bioinformatics bottleneck during 
